Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
Arun M. Unni, Bryant Harbourne, Min Hee Oh, et al.
eLife (2018) Vol. 7
Open Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Jimin Yuan, Xiaoduo Dong, Jiajun Yap, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 357
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Md Entaz Bahar, Hyun Joon Kim, Deok Ryong Kim
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 248
ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer
Reiko Sugiura, Ryosuke Satoh, Teruaki Takasaki
Cells (2021) Vol. 10, Iss. 10, pp. 2509-2509
Open Access | Times Cited: 233
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Oleg Timofeev, Philippe Giron, Steffen Lawo, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 22
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Matheus Henrique Dias, Anoek Friskes, Siying Wang, et al.
Cancer Discovery (2024) Vol. 14, Iss. 7, pp. 1276-1301
Open Access | Times Cited: 17
Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers
Takahiro Ito, Michael J. Young, Ruitong Li, et al.
Nature Genetics (2021) Vol. 53, Iss. 12, pp. 1664-1672
Closed Access | Times Cited: 101
Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
Pui–Kei Wu, Andrew Becker, Jong–In Park
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5436-5436
Open Access | Times Cited: 72
The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction
Jennifer E. Klomp, Jeffrey A. Klomp, Channing J. Der
Biochemical Society Transactions (2021) Vol. 49, Iss. 1, pp. 253-267
Closed Access | Times Cited: 63
Navigating the ERK1/2 MAPK Cascade
Ana Martín-Vega, Melanie H. Cobb
Biomolecules (2023) Vol. 13, Iss. 10, pp. 1555-1555
Open Access | Times Cited: 38
Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities
Liang Chang, Nancy Yoobin Jung, Adel Atari, et al.
Nature Genetics (2023) Vol. 55, Iss. 10, pp. 1709-1720
Closed Access | Times Cited: 25
LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Benjamin D. Stein, John R. Ferrarone, Eric E. Gardner, et al.
Cancer Discovery (2023) Vol. 13, Iss. 4, pp. 1002-1025
Open Access | Times Cited: 23
Mitogen signaling strength and duration can control cell cycle decisions
Ruth Nussinov, Wengang Zhang, Yonglan Liu, et al.
Science Advances (2024) Vol. 10, Iss. 27
Open Access | Times Cited: 14
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer
Ashenafi Bulle, Peng Liu, Kuljeet Seehra, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Comprehensive Analysis of ERK1/2 Substrates for Potential Combination Immunotherapies
Lei Yang, Liangzhen Zheng, Wee Joo Chng, et al.
Trends in Pharmacological Sciences (2019) Vol. 40, Iss. 11, pp. 897-910
Open Access | Times Cited: 62
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us
Geniver El Tekle, Tiziano Bernasocchi, Arun M. Unni, et al.
Trends in cancer (2021) Vol. 7, Iss. 9, pp. 823-836
Closed Access | Times Cited: 54
Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway
Jingtong Zhao, Zhijun Luo
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5158-5158
Open Access | Times Cited: 36
A guide to ERK dynamics, part 2: downstream decoding
Abhineet Ram, Devan Murphy, Nicholaus DeCuzzi, et al.
Biochemical Journal (2023) Vol. 480, Iss. 23, pp. 1909-1928
Open Access | Times Cited: 19
Inhibition of RAF dimers: it takes two to tango
Frazer A. Cook, Simon J. Cook
Biochemical Society Transactions (2020) Vol. 49, Iss. 1, pp. 237-251
Open Access | Times Cited: 40
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer
Nour Ghaddar, Shuo Wang, Bethany Woodvine, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 39
CRAF dimerization with ARAF regulates KRAS-driven tumor growth
Avinashnarayan Venkatanarayan, Jason Liang, Ivana Yen, et al.
Cell Reports (2022) Vol. 38, Iss. 6, pp. 110351-110351
Open Access | Times Cited: 28
Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma
Yone Kawe Lin, Wei Wu, Rovingaile Kriska Ponce, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 34, pp. 20776-20784
Open Access | Times Cited: 35
Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis
Shanshan Duan, Loredana Moro, Rui Qu, et al.
Cell Reports (2021) Vol. 37, Iss. 3, pp. 109870-109870
Open Access | Times Cited: 28
Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade
Hanying Wang, Xin He, Lei Zhang, et al.
Blood (2022) Vol. 139, Iss. 26, pp. 3752-3770
Open Access | Times Cited: 22
The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth
Bozhena Caratti, Miray Fidan, Giorgio Caratti, et al.
Science Signaling (2022) Vol. 15, Iss. 726
Closed Access | Times Cited: 20
Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer
MC. Rowell, Xavier Deschênes‐Simard, Stéphane Lopes-Paciência, et al.
Cell Cycle (2023) Vol. 22, Iss. 19, pp. 2172-2193
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top